{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:38:43Z","timestamp":1792395523184,"version":"4.4.0"},"reference-count":166,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007737","name":"St Jude Children's Research Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ymthe.2021.10.002","type":"journal-article","created":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T09:17:16Z","timestamp":1633771036000},"page":"3163-3178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Editing outside the body: Ex\u00a0vivo gene-modification for \u03b2-hemoglobinopathy cellular therapy"],"prefix":"10.1016","volume":"29","author":[{"given":"Tolulope O.","family":"Rosanwo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-7945","authenticated-orcid":false,"given":"Daniel E.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.10.002_bib1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.110.2865.543","article-title":"Sickle cell anemia a molecular disease","volume":"110","author":"Pauling","year":"1949","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.10.002_bib2","doi-asserted-by":"crossref","first-page":"e1001484","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010\u20132050: Modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"5","author":"Galanello","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2021.10.002_bib4","series-title":"GeneReviews","article-title":"Alpha-thalassemia","author":"Tamary","year":"2005"},{"key":"10.1016\/j.ymthe.2021.10.002_bib5","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbmt.2015.10.017","article-title":"Indications and results of HLA-identical sibling hematopoietic cell transplantation for sickle cell disease","volume":"22","author":"Walters","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2021.10.002_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev.med.47.1.11","article-title":"Gene transfer to hematopoietic stem cells: Implications for gene therapy of human disease","volume":"47","author":"Dunbar","year":"1996","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/331035a0","article-title":"Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells","volume":"331","author":"Dzierzak","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.10.002_bib9","series-title":"Renaissance of Sickle Cell Disease Research in the Genome Era","first-page":"295","article-title":"Genetically engineered cures: Gene therapy for sickle cell disease","author":"Malik","year":"2007"},{"key":"10.1016\/j.ymthe.2021.10.002_bib10","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib11","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41591-018-0301-6","article-title":"Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent \u03b2-thalassemia","volume":"25","author":"Marktel","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib13","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","article-title":"Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease","volume":"4","author":"Hsieh","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2021.10.002_bib14","series-title":"Bluebird bio provides updated findings from reported case of acute myeloid leukemia (AML) in LentiGlobin for sickle cell disease (SCD) gene therapy program","year":"2021"},{"key":"10.1016\/j.ymthe.2021.10.002_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France","volume":"105","author":"Bernaudin","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2021.10.002_bib16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib17","doi-asserted-by":"crossref","first-page":"21312","DOI":"10.1074\/jbc.M114.564625","article-title":"Characterization of genomic deletion efficiency mediated by clustered regularly interspaced short palindromic repeats (CRISPR)\/Cas9 nuclease system in mammalian cells","volume":"289","author":"Canver","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.10.002_bib18","doi-asserted-by":"crossref","first-page":"10620","DOI":"10.1073\/pnas.0902076106","article-title":"Chromosomal translocations induced at specified loci in human stem cells","volume":"106","author":"Brunet","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.10.002_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.tig.2008.08.007","article-title":"MMEJ repair of double-strand breaks (director\u2019s cut): Deleted sequences and alternative endings","volume":"24","author":"McVey","year":"2008","journal-title":"Trends Genet."},{"key":"10.1016\/j.ymthe.2021.10.002_bib20","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.4161\/cc.7.18.6679","article-title":"DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells","volume":"7","author":"Mao","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ymthe.2021.10.002_bib21","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/bloodadvances.2019000820","article-title":"Genome editing of HBG1 and HBG2 to induce fetal hemoglobin","volume":"3","author":"M\u00e9tais","year":"2019","journal-title":"Blood Adv."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2021.10.002_bib22","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2019-130256","article-title":"EDIT-301: An experimental autologous cell therapy comprising Cas12a-RNP modified mPB-CD34+ cells for the potential treatment of SCD","volume":"134","author":"De Dreuzy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib23","doi-asserted-by":"crossref","first-page":"e0208237","DOI":"10.1371\/journal.pone.0208237","article-title":"CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells","volume":"14","author":"Chung","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2021.10.002_bib24","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1073\/pnas.1612075113","article-title":"Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and \u03b2-thalassemia","volume":"113","author":"Ye","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.10.002_bib25","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.3324\/haematol.2018.215178","article-title":"Correction of IVS I-110(G>A) \u03b2-thalassemia by CRISPR\/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells","volume":"104","author":"Patsali","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2021.10.002_bib26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/bloodadvances.2020001996","article-title":"Correction of \u03b2-thalassemia by CRISPR\/Cas9 editing of the \u03b1-globin locus in human hematopoietic stem cells","volume":"5","author":"Pavani","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2021.10.002_bib27","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2021.10.002_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41591-020-0790-y","article-title":"Therapeutic base editing of human hematopoietic stem cells","volume":"26","author":"Zeng","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib29","article-title":"Identification of novel HPFH-like mutations by CRISPR base editing that elevates the expression of fetal hemoglobin","author":"Ravi","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2021.10.002_bib30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/crispr.2020.0144","article-title":"Rationally designed base editors for precise editing of the sickle cell disease mutation","volume":"4","author":"Chu","year":"2021","journal-title":"CRISPR J."},{"key":"10.1016\/j.ymthe.2021.10.002_bib31","first-page":"8096","article-title":"Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease","volume":"14","author":"Rouet","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/156652307779940216","article-title":"Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy","volume":"7","author":"P\u00e2ques","year":"2007","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2021.10.002_bib33","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nbt0805-915","article-title":"The zinc finger nuclease monopoly","volume":"23","author":"Scott","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cbpa.2012.06.007","article-title":"Advances in targeted genome editing","volume":"16","author":"Perez-Pinera","year":"2012","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib35","series-title":"Prokaryotic Diversity: Mechanisms and Significance","first-page":"39","article-title":"A putative RNA-interference-based immune system in prokaryotes: the epitome of prokaryotic genomic diversity","author":"Koonin","year":"2010"},{"key":"10.1016\/j.ymthe.2021.10.002_bib36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.10.002_bib37","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.10.002_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.10.002_bib39","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib40","article-title":"High-level correction of the sickle mutation amplified in\u00a0vivo during erythroid differentiation","author":"Magis","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2021.10.002_bib41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2021.10.002_bib42","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.bmt.1702151","article-title":"Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation","volume":"25","author":"Andreani","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymthe.2021.10.002_bib44","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1182\/blood-2014-12-615948","article-title":"Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells","volume":"125","author":"Hoban","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib45","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/stem.2935","article-title":"Improving gene editing outcomes in human hematopoietic stem and progenitor cells by temporal control of DNA repair","volume":"37","author":"Lomova","year":"2019","journal-title":"Stem Cells"},{"key":"10.1016\/j.ymthe.2021.10.002_bib46","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood.2020008503","article-title":"Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem\/progenitor cells","volume":"137","author":"De Ravin","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib47","doi-asserted-by":"crossref","first-page":"7955","DOI":"10.1093\/nar\/gkz475","article-title":"Highly efficient editing of the \u03b2-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease","volume":"47","author":"Park","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2021.10.002_bib48","doi-asserted-by":"crossref","first-page":"eabf2444","DOI":"10.1126\/scitranslmed.abf2444","article-title":"Development of \u03b2-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease","volume":"13","author":"Lattanzi","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00000441-194804000-00008","article-title":"The significance of the paucity of sickle cells in newborn Negro infants","volume":"215","author":"Watson","year":"1948","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.ymthe.2021.10.002_bib50","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib51","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/S0140-6736(15)01341-0","article-title":"Fetal haemoglobin in sickle-cell disease: From genetic epidemiology to new therapeutic strategies","volume":"387","author":"Lettre","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2021.10.002_bib52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9343(60)90003-6","article-title":"Hereditary persistence of fetal hemoglobin. A family study","volume":"29","author":"Herman","year":"1960","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib53","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jama.1961.73040380028011b","article-title":"Amelioration of sickle cell disease by persistent fetal hemoglobin","volume":"177","author":"Jackson","year":"1961","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2021.10.002_bib54","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(72)92592-5","article-title":"Benign sickle-cell anaemia","volume":"2","author":"Perrine","year":"1972","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2021.10.002_bib55","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1749-6632.1998.tb10460.x","article-title":"Molecular basis of hereditary persistence of fetal hemoglobin","volume":"850","author":"Forget","year":"1998","journal-title":"Ann. N Y Acad. Sci."},{"key":"10.1016\/j.ymthe.2021.10.002_bib56","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ng2108","article-title":"A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15","volume":"39","author":"Menzel","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2021.10.002_bib57","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1126\/science.1165409","article-title":"Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A","volume":"322","author":"Sankaran","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.10.002_bib58","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1073\/pnas.0711566105","article-title":"Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia","volume":"105","author":"Uda","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.10.002_bib59","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.cell.2018.03.016","article-title":"Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2021.10.002_bib60","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41588-018-0085-0","article-title":"Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding","volume":"50","author":"Martyn","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2021.10.002_bib61","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1073\/pnas.1303976110","article-title":"Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A","volume":"110","author":"Xu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.10.002_bib62","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/s41588-019-0453-4","article-title":"Rational targeting of a NuRD subcomplex guided by comprehensive in\u00a0situ mutagenesis","volume":"51","author":"Sher","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2021.10.002_bib63","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.aad3312","article-title":"Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin","volume":"351","author":"Masuda","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.10.002_bib64","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41588-021-00798-y","article-title":"Transcription factor competition at the \u03b3-globin promoters controls hemoglobin switching","volume":"53","author":"Liu","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2021.10.002_bib65","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1126\/science.1242088","article-title":"An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level","volume":"342","author":"Bauer","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.10.002_bib66","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nature15521","article-title":"BCL11A enhancer dissection by Cas9-mediated in\u00a0situ saturating mutagenesis","volume":"527","author":"Canver","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.10.002_bib67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ajhg.2016.05.030","article-title":"BCL11A haploinsufficiency causes an intellectual disability syndrome and dysregulates transcription","volume":"99","author":"Dias","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2021.10.002_bib68","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nmeth.3554","article-title":"Functional footprinting of regulatory DNA","volume":"12","author":"Vierstra","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2021.10.002_bib69","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2016-08-736249","article-title":"Strict in\u00a0vivo specificity of the Bcl11a erythroid enhancer","volume":"128","author":"Smith","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib70","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.omtm.2016.12.009","article-title":"Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone-marrow-derived CD34+ hematopoietic stem and progenitor cells","volume":"4","author":"Chang","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2021.10.002_bib71","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib72","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1172\/JCI140189","article-title":"BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity","volume":"130","author":"Demirci","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2021.10.002_bib73","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib74","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM198404053101401","article-title":"Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea","volume":"310","author":"Letvin","year":"1984","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib75","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Risk factors and stratification, prophylaxis, and treatment","volume":"22","author":"Dalle","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2021.10.002_bib76","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2018-99-116998","article-title":"Ex\u00a0vivo gene-edited cell therapy for sickle cell disease: Disruption of the BCL11A erythroid enhancer with zinc finger nucleases increases fetal hemoglobin in plerixafor mobilized human CD34+ cells","volume":"132","author":"Moran","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib77","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib78","doi-asserted-by":"crossref","first-page":"10133","DOI":"10.1038\/s41598-020-66309-x","article-title":"Comparative targeting analysis of KLF1, BCL11A, and HBG1\/2 in CD34+ HSPCs by CRISPR\/Cas9 for the induction of fetal hemoglobin","volume":"10","author":"Lamsfus-Calle","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2021.10.002_bib79","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.molcel.2020.11.006","article-title":"ZNF410 uniquely activates the NuRD component CHD4 to silence fetal hemoglobin expression","volume":"81","author":"Lan","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2021.10.002_bib80","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41588-021-00843-w","article-title":"ZNF410 represses fetal globin by singular control of CHD4","volume":"53","author":"Vinjamur","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2021.10.002_bib81","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm.4170","article-title":"A genome-editing strategy to treat \u03b2-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition","volume":"22","author":"Traxler","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib82","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.omtm.2018.12.008","article-title":"TALEN-mediated gene editing of HBG in human hematopoietic stem cells leads to therapeutic fetal hemoglobin induction","volume":"12","author":"Lux","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2021.10.002_bib83","doi-asserted-by":"crossref","first-page":"eaaw3768","DOI":"10.1126\/scitranslmed.aaw3768","article-title":"Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates","volume":"11","author":"Humbert","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib84","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.17167","article-title":"Induction of therapeutic levels of HbF in genome-edited primary \u03b2039-thalassaemia haematopoietic stem and progenitor cells","volume":"192","author":"Mingoia","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib85","doi-asserted-by":"crossref","first-page":"eaay9392","DOI":"10.1126\/sciadv.aay9392","article-title":"Editing a \u03b3-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype","volume":"6","author":"Weber","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2021.10.002_bib86","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2017-10-811505","article-title":"Induction of fetal hemoglobin synthesis by CRISPR\/Cas9-mediated editing of the human \u03b2-globin locus","volume":"131","author":"Antoniani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib87","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1182\/blood.V90.11.4602","article-title":"The human \u03b2 globin locus introduced by YAC transfer exhibits a specific and reproducible pattern of developmental regulation in transgenic mice","volume":"90","author":"Porcu","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib88","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood-2019-01-895094","article-title":"Editing aberrant splice sites efficiently restores \u03b2-globin expression in \u03b2-thalassemia","volume":"133","author":"Xu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib89","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41591-021-01284-y","article-title":"Gene replacement of \u03b1-globin with \u03b2-globin restores hemoglobin balance in \u03b2-thalassemia-derived hematopoietic stem and progenitor cells","volume":"27","author":"Cromer","year":"2021","journal-title":"Nat. Med."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2021.10.002_bib90","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-141498","article-title":"Adenosine base editing of \u03b3-globin promoters induces fetal hemoglobin and inhibit erythroid sickling","volume":"136","author":"Mayuranathan","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib91","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41587-020-0412-8","article-title":"Continuous evolution of SpCas9 variants compatible with non-G PAMs","volume":"38","author":"Miller","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.10.002_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V69.1.1.1","article-title":"Subunit assembly of hemoglobin: An important determinant of hematologic phenotype","volume":"69","author":"Bunn","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib94","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.amjmed.2008.12.020","article-title":"Complications associated with sickle cell trait: A brief narrative review","volume":"122","author":"Tsaras","year":"2009","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib95","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.10.002_bib96","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.15936","article-title":"Recognition of research participants\u2019 need for autonomy: Remembering the legacy of Henrietta Lacks","author":"Wolinetz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2021.10.002_bib97","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/13557858.2011.563283","article-title":"Living with sickle cell disease: Traversing \u201crace\u201d and identity","volume":"16","author":"Royal","year":"2011","journal-title":"Ethn. Health"},{"key":"10.1016\/j.ymthe.2021.10.002_bib98","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/DBP.0000000000000381","article-title":"Perceived racial bias and health-related stigma among youth with sickle cell disease","volume":"38","author":"Wakefield","year":"2017","journal-title":"J.\u00a0Dev. Behav. Pediatr."},{"key":"10.1016\/j.ymthe.2021.10.002_bib99","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1056\/NEJMp2022125","article-title":"When actions speak louder than words\u2014Racism and sickle cell disease","volume":"383","author":"Power-Hays","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamapediatrics.2020.7147","article-title":"Gene therapy for sickle cell disease\u2014A debt to be paid","volume":"175","author":"Ozuah","year":"2021","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.ymthe.2021.10.002_bib101","first-page":"1052","article-title":"Willingness of minorities to participate in biomedical studies: confirmatory findings from a follow-up study using the Tuskegee Legacy Project Questionnaire","volume":"99","author":"Katz","year":"2007","journal-title":"J.\u00a0Natl. Med. Assoc."},{"key":"10.1016\/j.ymthe.2021.10.002_bib102","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2105\/AJPH.2011.300279","article-title":"Challenging assumptions about minority participation in US clinical research","volume":"101","author":"Fisher","year":"2011","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.ymthe.2021.10.002_bib103","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0030019","article-title":"Are racial and ethnic minorities less willing to participate in health research?","volume":"3","author":"Wendler","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib104","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1740774513519876","article-title":"Attitudes toward clinical trials among patients with sickle cell disease","volume":"11","author":"Haywood","year":"2014","journal-title":"Clin. Trials"},{"key":"10.1016\/j.ymthe.2021.10.002_bib105","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/s41436-018-0409-6","article-title":"A CRISPR focus on attitudes and beliefs toward somatic genome editing from stakeholders within the sickle cell disease community","volume":"21","author":"Persaud","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib106","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/23294515.2020.1818876","article-title":"The meaning of informed consent: Genome editing clinical trials for sickle cell disease","volume":"11","author":"Desine","year":"2020","journal-title":"AJOB Empir. Bioeth."},{"key":"10.1016\/j.ymthe.2021.10.002_bib107","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/0033354919881438","article-title":"Reducing health care disparities in sickle cell disease: A review","volume":"134","author":"Lee","year":"2019","journal-title":"Public Health Rep."},{"key":"10.1016\/j.ymthe.2021.10.002_bib108","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/14653240902849788","article-title":"Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: Time for a moratorium?","volume":"11","author":"Fitzhugh","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2021.10.002_bib109","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3324\/haematol.2017.187047","article-title":"Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: Interim results","volume":"103","author":"Boulad","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2021.10.002_bib110","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","volume":"22","author":"Ferrari","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2021.10.002_bib111","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1566523214666141127095336","article-title":"Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of \u03b2-thalassemia and sickle cell disease","volume":"15","author":"Negre","year":"2015","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2021.10.002_bib112","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1182\/bloodadvances.2021004232","article-title":"Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease","volume":"5","author":"Leonard","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2021.10.002_bib113","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.omtm.2019.10.017","article-title":"Low-dose busulfan reduces human CD34+ cell doses required for engraftment in c-kit mutant immunodeficient mice","volume":"15","author":"Leonard","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2021.10.002_bib114","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","article-title":"Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning","volume":"117","author":"Majhail","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.10.002_bib116","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib117","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41587-020-0551-y","article-title":"Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking","volume":"38","author":"Ferrari","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib118","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","article-title":"Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response","volume":"24","author":"Schiroli","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2021.10.002_bib119","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.stem.2020.12.002","article-title":"UM171 preserves epigenetic marks that are reduced in ex\u00a0vivo culture of human HSCs via potentiation of the CLR3-KBTBD4 complex","volume":"28","author":"Chagraoui","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2021.10.002_bib120","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","article-title":"DNA double-strand break repair-pathway choice in somatic mammalian cells","volume":"20","author":"Scully","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib121","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.molcel.2021.03.032","article-title":"Impact of chromatin context on Cas9-induced DNA double-strand break repair pathway balance","volume":"81","author":"Schep","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2021.10.002_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncb3452","article-title":"The control of DNA repair by the cell cycle","volume":"19","author":"Hustedt","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib123","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature20134","article-title":"CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells","volume":"539","author":"Dever","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.10.002_bib124","doi-asserted-by":"crossref","first-page":"360ra134","DOI":"10.1126\/scitranslmed.aaf9336","article-title":"Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells","volume":"8","author":"DeWitt","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib125","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.10.002_bib126","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2021.10.002_bib127","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nmeth.4284","article-title":"Mapping the genomic landscape of CRISPR-Cas9 cleavage","volume":"14","author":"Cameron","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2021.10.002_bib128","doi-asserted-by":"crossref","first-page":"eabe5496","DOI":"10.1126\/sciadv.abe5496","article-title":"Quantification of Cas9 binding and cleavage across diverse guide sequences maps landscapes of target engagement","volume":"7","author":"Boyle","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2021.10.002_bib129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41596-020-00431-y","article-title":"Tools for experimental and computational analyses of off-target editing by programmable nucleases","volume":"16","author":"Bao","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2021.10.002_bib130","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/crispr.2020.0053","article-title":"Evaluation of homology-independent CRISPR-Cas9 off-target assessment methods","volume":"3","author":"Chaudhari","year":"2020","journal-title":"CRISPR J."},{"key":"10.1016\/j.ymthe.2021.10.002_bib131","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-biochem-013118-111730","article-title":"Evaluating and enhancing target specificity of gene-editing nucleases and deaminases","volume":"88","author":"Kim","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ymthe.2021.10.002_bib132","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.molcel.2020.02.023","article-title":"Highly parallel profiling of Cas9 variant specificity","volume":"78","author":"Schmid-Burgk","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2021.10.002_bib133","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","article-title":"Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors","volume":"569","author":"Gr\u00fcnewald","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.10.002_bib134","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41586-019-1314-0","article-title":"Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis","volume":"571","author":"Zhou","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.10.002_bib135","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1126\/science.aaw7166","article-title":"Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice","volume":"364","author":"Jin","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.10.002_bib136","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1126\/science.aav9973","article-title":"Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos","volume":"364","author":"Zuo","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.10.002_bib137","article-title":"Human genetic diversity modifies therapeutic gene editing off-target potential","author":"Cancellieri","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2021.10.002_bib138","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/sj.bmt.1702066","article-title":"Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation","volume":"24","author":"P\u00e9rez-Sim\u00f3n","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymthe.2021.10.002_bib139","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/bmt.2010.320","article-title":"Importance of blood graft characteristics in auto-SCT: Implications for optimizing mobilization regimens","volume":"46","author":"Jantunen","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymthe.2021.10.002_bib140","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1182\/blood.2019002350","article-title":"Clonal tracking in gene therapy patients reveals a diversity of human hematopoietic differentiation programs","volume":"135","author":"Six","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib141","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-018-0497-0","article-title":"Population dynamics of normal human blood inferred from somatic mutations","volume":"561","author":"Lee-Six","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.10.002_bib142","doi-asserted-by":"crossref","first-page":"eaan0820","DOI":"10.1126\/scitranslmed.aan0820","article-title":"Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1","volume":"9","author":"Schiroli","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib143","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41467-020-20792-y","article-title":"The TRACE-seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.10.002_bib144","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1182\/bloodadvances.2019001196","article-title":"Longitudinal assessment of clonal mosaicism in human hematopoiesis via mitochondrial mutation tracking","volume":"3","author":"Lareau","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2021.10.002_bib145","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1182\/blood.2019002227","article-title":"Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion","volume":"135","author":"Park","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib146","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.2019002721","article-title":"Hematopoietic stem cell function in \u03b2-thalassemia is impaired and is rescued by targeting the bone marrow niche","volume":"136","author":"Aprile","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib147","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1172\/JCI123191","article-title":"Bone marrow stromal cells from \u03b2-thalassemia patients have impaired hematopoietic supportive capacity","volume":"129","author":"Crippa","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2021.10.002_bib148","doi-asserted-by":"crossref","first-page":"e27778","DOI":"10.1002\/pbc.27778","article-title":"Hydroxyurea for children with sickle cell anemia: Prescribe it early and often","volume":"66","author":"Ware","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ymthe.2021.10.002_bib149","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/ajh.25937","article-title":"Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease","volume":"95","author":"Hebert","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib150","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/bloodadvances.2019000882","article-title":"End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain","volume":"3","author":"Farrell","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2021.10.002_bib151","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJM198409203111207","article-title":"Bone-marrow transplantation in a patient with sickle-cell anemia","volume":"311","author":"Johnson","year":"1984","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2021.10.002_bib152","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2018-99-113480","article-title":"Current results of LentiGlobin gene therapy in patients with severe sickle cell disease treated under a refined protocol in the phase 1 HgB-206 study","volume":"132","author":"Tisdale","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib153","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.17323","article-title":"Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia","volume":"194","author":"Ware","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib154","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41379-019-0325-6","article-title":"Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature","volume":"32","author":"Li","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ymthe.2021.10.002_bib155","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0141076816651037","article-title":"Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study","volume":"109","author":"Seminog","year":"2016","journal-title":"J.\u00a0R. Soc. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib156","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib157","first-page":"1185","article-title":"Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation","volume":"135","author":"Ghannam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib158","article-title":"Clonal hematopoiesis in sickle cell disease","author":"Liggett","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2021.10.002_bib159","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2021.10.002_bib160","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021011121","article-title":"Clonal hematopoiesis in sickle cell disease","author":"Pincez","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.10.002_bib161","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.ymthe.2021.03.010","article-title":"A pause in gene therapy: Reflecting on the unique challenges of sickle cell disease","volume":"29","author":"Leonard","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.10.002_bib162","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle systems for enabling gene therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.10.002_bib163","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2021.10.002_bib164","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/bloodadvances.2020002948","article-title":"A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy","volume":"5","author":"Badawy","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2021.10.002_bib165","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbmt.2014.12.007","article-title":"Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease","volume":"21","author":"Bhatia","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2021.10.002_bib166","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.bbmt.2017.01.007","article-title":"Enhanced long-term brain magnetic resonance imaging evaluation of children with sickle cell disease after hematopoietic cell transplantation","volume":"23","author":"Green","year":"2017","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621004962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621004962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T22:54:19Z","timestamp":1714604059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621004962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":166,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1525001621004962"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.10.002","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Editing outside the body: Ex\u00a0vivo gene-modification for \u03b2-hemoglobinopathy cellular therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}